$2
Insights on Amylyx Pharmaceuticals, Inc.
Revenue is up for the last 7 quarters, 285.0K → 108.44M (in $), with an average increase of 37.0% per quarter
Netprofit is down for the last 3 quarters, 22.07M → 4.73M (in $), with an average decrease of 41.4% per quarter
In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 137.8%
0.5%
Downside
Day's Volatility :4.33%
Upside
3.85%
1.0%
Downside
52 Weeks Volatility :93.77%
Upside
93.7%
Period | Amylyx Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -86.67% | -0.5% | 0.0% |
6 Months | -88.76% | 5.9% | 0.0% |
1 Year | -93.48% | 3.1% | -1.9% |
3 Years | -88.88% | 14.2% | -21.8% |
Market Capitalization | 140.6M |
Book Value | $6.52 |
Earnings Per Share (EPS) | 0.7 |
PE Ratio | 2.87 |
Wall Street Target Price | 4.25 |
Profit Margin | 12.94% |
Operating Margin TTM | 1.78% |
Return On Assets TTM | 5.34% |
Return On Equity TTM | 12.73% |
Revenue TTM | 380.8M |
Revenue Per Share TTM | 5.66 |
Quarterly Revenue Growth YOY | 395.5% |
Gross Profit TTM | -74.2M |
EBITDA | 39.9M |
Diluted Eps TTM | 0.7 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.6 |
EPS Estimate Next Year | -0.77 |
EPS Estimate Current Quarter | 0.23 |
EPS Estimate Next Quarter | 0.28 |
What analysts predicted
Upside of 112.5%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.4M | - |
Net Income | -14.8M | - |
Net Profit Margin | -1.0K% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 650.0K | ↓ 54.42% |
Net Income | -44.8M | ↑ 202.63% |
Net Profit Margin | -6.9K% | ↓ 5859.01% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 285.0K | ↓ 56.15% |
Net Income | -87.9M | ↑ 96.0% |
Net Profit Margin | -30.8K% | ↓ 23936.74% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 22.2M | ↑ 7700.0% |
Net Income | -198.4M | ↑ 125.74% |
Net Profit Margin | -892.38% | ↑ 29942.36% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 380.8M | ↑ 1612.94% |
Net Income | 49.3M | ↓ 124.84% |
Net Profit Margin | 12.94% | ↑ 905.32% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 345.0K | - |
Net Income | -53.8M | ↓ 0.58% |
Net Profit Margin | -15.6K% | - |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 21.9M | ↑ 6243.48% |
Net Income | -42.7M | ↓ 20.56% |
Net Profit Margin | -195.13% | ↑ 15386.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 71.4M | ↑ 226.38% |
Net Income | 1.6M | ↓ 103.68% |
Net Profit Margin | 2.2% | ↑ 197.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 98.2M | ↑ 37.5% |
Net Income | 22.1M | ↑ 1303.31% |
Net Profit Margin | 22.47% | ↑ 20.27% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 102.7M | ↑ 4.56% |
Net Income | 20.9M | ↓ 5.35% |
Net Profit Margin | 20.35% | ↓ 2.12% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 108.4M | ↑ 5.61% |
Net Income | 4.7M | ↓ 77.36% |
Net Profit Margin | 4.36% | ↓ 15.99% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.2M | - |
Total Liabilities | 28.6M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 14.1M | ↑ 338.01% |
Total Liabilities | 80.8M | ↑ 182.85% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 105.6M | ↑ 648.82% |
Total Liabilities | 256.8M | ↑ 217.69% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 391.5M | ↑ 270.64% |
Total Liabilities | 50.8M | ↓ 80.2% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 517.5M | ↑ 32.19% |
Total Liabilities | 84.0M | ↑ 65.25% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 181.4M | ↓ 19.44% |
Total Liabilities | 37.4M | ↑ 15.3% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 391.5M | ↑ 115.74% |
Total Liabilities | 50.8M | ↑ 35.9% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 408.0M | ↑ 4.22% |
Total Liabilities | 55.3M | ↑ 8.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 453.6M | ↑ 11.18% |
Total Liabilities | 67.2M | ↑ 21.54% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 466.6M | ↑ 2.87% |
Total Liabilities | 48.2M | ↓ 28.32% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 517.5M | ↑ 10.9% |
Total Liabilities | 84.0M | ↑ 74.38% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.7M | - |
Investing Cash Flow | -151.0K | - |
Financing Cash Flow | 668.0K | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -36.7M | ↑ 243.38% |
Investing Cash Flow | -151.0K | ↑ 0.0% |
Financing Cash Flow | 46.8M | ↑ 6909.43% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -74.8M | ↑ 103.83% |
Investing Cash Flow | -46.4M | ↑ 30632.45% |
Financing Cash Flow | 158.5M | ↑ 238.52% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -179.9M | ↑ 140.47% |
Investing Cash Flow | -239.0M | ↑ 414.99% |
Financing Cash Flow | 431.8M | ↑ 172.41% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -43.1M | ↓ 7.28% |
Investing Cash Flow | 84.0M | ↑ 1783.48% |
Financing Cash Flow | 199.6M | ↓ 24209.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -49.7M | ↑ 15.37% |
Investing Cash Flow | -228.2M | ↓ 371.51% |
Financing Cash Flow | 232.2M | ↑ 16.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.1M | ↓ 89.79% |
Investing Cash Flow | 56.0M | ↓ 124.54% |
Financing Cash Flow | 1.0M | ↓ 99.55% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.6M | ↓ 269.74% |
Investing Cash Flow | 123.2M | ↑ 120.06% |
Financing Cash Flow | 1.4M | ↑ 33.08% |
Sell
Neutral
Buy
Amylyx Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Amylyx Pharmaceuticals, Inc. | -29.72% | -88.76% | -93.48% | -88.88% | -88.88% |
Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Amylyx Pharmaceuticals, Inc. | 2.87 | 2.87 | NA | -1.6 | 0.13 | 0.05 | NA | 6.52 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Amylyx Pharmaceuticals, Inc. | Buy | $140.6M | -88.88% | 2.87 | 12.94% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Vanguard Group Inc
BlackRock Inc
Viking Global Investors LP
Morgan Stanley - Brokerage Accounts
Goldman Sachs Group Inc
Stonepine Capital Management Llc
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.
Organization | Amylyx Pharmaceuticals, Inc. |
Employees | 384 |
CEO | Mr. Joshua B. Cohen |
Industry | Services |
Jianzhi Education Technology Group Company Ltd.
$2.00
-0.5%
Carrols Restaurant Group Inc
$2.00
-0.5%
Bristow Group Inc
$2.00
-0.5%
America's Car-mart Inc
$2.00
-0.5%
Tilly's Inc
$2.00
-0.5%
Destination Xl Group Inc
$2.00
-0.5%
Gigacloud Technology Inc
$2.00
-0.5%
Barrett Business Services Inc
$2.00
-0.5%
Telesat Corp
$2.00
-0.5%